Starpharma (SPL) Stock Price, News & Analysis

Company Overview

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 351,391 shs
• Average Volume: N/A
• Market Capitalization: A$43.90 million
• P/E Ratio: N/A
• Dividend Yield: 9.30%
• Price Target: N/A
• Consensus Rating: N/A

SPL Stock Analysis - Frequently Asked Questions

How were Starpharma's earnings last quarter?

Starpharma Holdings Limited (ASX:SPL) issued its quarterly earnings data on Wednesday, February, 27th. The company reported ($0.02) earnings per share for the quarter. Starpharma had a negative trailing twelve-month return on equity of 26.10% and a negative net margin of 91.45%.

What other stocks do shareholders of Starpharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Starpharma investors own include Starpharma (SPHRY), Allena Pharmaceuticals (ALNA), Aurora Cannabis (ACBFF), Ampliphi Biosciences (APHB), AstraZeneca (AZN), Arbutus Biopharma (ABUS) and AcelRx Pharmaceuticals (ACRX).

Company Calendar

• Last Earnings: 2/27/2019
• Today: 10/22/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:SPL
• CIK: N/A
• Web: www.starpharma.com
• Phone: +61-3-85322700
• Fax: N/A
• Employees: 45
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$8.16 million
• Net Margins: -91.45%
• Pretax Margin: N/A
• Return on Equity: -26.10%
• Return on Assets: -11.48%

Debt

• Debt-to-Equity Ratio: 12.55
• Current Ratio: 4.94
• Quick Ratio: 5.65

Sales & Book Value

• Annual Sales: A$9.76 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 10.42
• Book Value: A$0.07 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 417,370,000
• Free Float: N/A
• Market Cap: A$43.90 million
• Optionable: Not Optionable
• Beta: 0.77